flunisolide (nasalide) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Flunisolide is a synthetic corticosteroid. It is administered either as an oral metered-dose inhaler for the treatment of asthma or as a nasal spray for treating allergic rhinitis. Corticosteroids are naturally occurring hormones that prevent or suppress inflammation and immune responses. When given as an intranasal spray, flunisolide reduces watery nasal discharge (rhinorrhea), nasal congestion, postnasal drip, sneezing, and itching oat the back of the throat that are common allergic symptoms. Flunisolide is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flunisolide binds to plasma transcortin, and it becomes active when it is not bound to transcortin. It is used for the maintenance treatment of asthma as a prophylactic therapy. Flunisolide is marketed as AeroBid, Nasalide, Nasarel.   NCATS

Chemistry

  • SMILES: CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
  • InChIKey: XSFJVAJPIHIPKU-XWCQMRHXSA-N
  • Mol. Mass: 434.4977
  • ALogP: 2.27
  • ChEMBL Molecule:
    flunisolide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2.1237
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

6 alpha-fluoro-11 beta,16 alpha,17,21- tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16, 17-acetal with acetone | 6 alpha-fluorodihydroxy-16 alpha,17 alpha-isopropylidenedioxy-1,4-pregnadiene-3,20- dione | aerobid | aerospan | aerospan hfa | apo-flunisolide | bronalide | elan brand 1 of flunisolide | elan brand 2 of flunisolide | flunisolida | flunisolide | flunisolide, (6beta,11beta,16alpha)-isomer | flunisolide anhydrous | flunisolide hemihydrate, (6alpha,11beta,16alpha)-isomer | flunisolide hfa | flunisolide hydrofluoroalkane | flunisolidum | inhacort | nasalide | nasarel | ratio-flunisolide | rhinalar | rs-3999 | syntaris | syntaris hayfever

Organizations (14)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (2)


 

Asthma

Rhinitis, Allergic (approved 2002)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Asthma (Phase 1/Phase 2)

Lung Diseases (Phase 1/Phase 2)

Rhinitis, Allergic, Perennial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue